Orphan designation: Pamrevlumab Treatment of Duchenne muscular dystrophy, 16/12/2019 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 19 November 2024 - 9:31

Orphan designation: Pamrevlumab Treatment of Duchenne muscular dystrophy, 16/12/2019 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2234

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters